MENU
PRODUCT LIST
HOME
FAQ
CONTACT US
TESTIMONIALS
ORDER STATUS
ABOUT US
Back
PRODUCT LIST
Amalaki
ProSolution
ProVestra
Slimonil Men
VigRX
VigRX Plus
Volume Pills
VP-GL
Penisole
Septilin
Ashwagandha
Abana
Arjuna
Ayurslim
Brahmi
Confido
Cystone
Diabecon
Enhance 9
Evecare
Gasex
Geriforte
Hair Loss Cream
Herbal Max Gun Power
Herbolax
Himcolin
Himplasia
Karela
Lasuna
LIV.52
LIV.52 Drops
Lukol
Man XXX
Menosan
Mentat
Neem
Ophthacare
Pilex
Purim
Reosto
Rumalaya
Rumalaya Fort
Shallaki
Shuddha Guggulu
Speman
Styplon
Tentex Forte
Tentex Royal
V-gel
VPXL
MY CART
3
VPXL
60 caps
x
3 bottles
$ 114.99
Ashwagandha
60 caps
x
2 bottles
$ 50.99
Lasuna
60 caps
x
2 bottles
$ 34.99
Select currency
USD
EUR
CZK
Select language
English
Deutsch
Czech
Express cestine
3
Convenience Ensured
Place the order whenever and wherever you want
Payment Methods
Shipping Option
Shopping cart
Product
Quantity
Price
Total
VPXL
60 caps
x
3 bottles
$ 114.99
$ 114.99
$ 114.99
Ashwagandha
60 caps
x
2 bottles
$ 50.99
$ 50.99
$ 50.99
Lasuna
60 caps
x
2 bottles
$ 34.99
$ 34.99
$ 34.99
Shipping method:
Airmail Service
FREE
Trackable Service
$ 30.00
$ 200.97
There is no review for this product at the moment, but you can be the first to add or you can read more in Testimonials Page about related products.
TRY OUR ED PACK
Social bookmarks:
News
Are UK students at risk of more deadly meningitis outbreaks?
The worst seems to be over, but questions remain about why this happened and whether it could happen ...
Ultrasound delays putting pregnant women and cancer patients at risk, sonographers say
Demand for ultrasound has increased but too few people are being trained for the job, sonographers warn. ...
Our daughter battled Meningitis B despite being vaccinated in 'very rare' case
After Noa-Rose became critically ill, the four-year-old spent two weeks fighting for her life.
Screen time for under-fives should be limited to one hour a day, parents told
New government guidance also suggests children under-two should not be watching screens alone.
Bookmark
Sitemap
Subscribe to the news
